Form 4: Neumora Therapeutics Director Alaa Halawa Reports Acquisition and Disposal of Securities

Director Alaa Halawa reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Summary

• On June 13, 2024, Alaa Halawa, a director of Neumora Therapeutics, Inc., reported transactions involving the company's securities.
• Halawa acquired 20,100 restricted stock units (RSUs), each convertible to one share of common stock upon vesting, at a price of $0.
• Additionally, Halawa acquired options to purchase 28,571 shares of common stock at an exercise price of $9.95.
• The RSUs and stock options vest on the earlier of June 13, 2025, or immediately before the next Annual Meeting following June 13, 2024.
• Halawa also disposed of 20,100 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The vesting of RSUs and stock options is contingent upon the earlier of a specific date or the timing of the next Annual Meeting, indicating a potential future increase in the director's holdings.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates